查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529689

SGLT2抑制劑市場規模、佔有率、趨勢分析報告：按藥物、適應症、按分銷管道、按地區、細分市場預測，2024-2030年

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 159 Pages | 商品交期: 2-10個工作天內

價格

SGLT2 抑制劑市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，SGLT2抑制劑的全球市場規模預計將達到294.3億美元，預測期內複合年成長率為7.71%。

美國糖尿病協會 (ADA)、歐洲糖尿病研究學會 (EASD) 和歐洲心臟病學會 (ESC) 等領先醫療組織的建議和支持指南表明，鈉-葡萄糖共同輸送體2 (SGLT2) 的抑製作用超過了葡萄糖的抑製作用我支持醫學。例如，2023年8月，歐洲心臟病學會（ESC）綜合了2021年以來進行的近十多項新臨床試驗的結果，包括EMPEROR-Preserved、DELIVER、STRONG-HF和IRONMAN，宣布對心臟衰竭指南進行重點更新。 2023 年 ESC 大會上提出的更新指南引入了使用 SGLT2 抑制劑治療射血分數輕度降低 (HFmrEF)心臟衰竭患者的新建議。

此外，未來幾年需要透析的患者數量將會增加，這表明對 SGLT2 抑制劑等用於治療 CKD 患者的藥物的需求很高。 2023 年 11 月，NICE（國家健康與照護卓越研究所）發布了指引草案，建議慢性腎臟病(CKD) 患者使用Empagliflozin（一種 SGLT2 抑制劑）。Empagliflozin已被證明可以有效減緩腎衰竭的進展並降低心臟病和中風的風險。 NICE 建議向 CKD 各個階段的患者提供這種治療。此類藥物監管機構的建議將在預測期內增加對藥物的需求。

老年人更容易患第 2 型糖尿病和心臟衰竭，而藥物對這些疾病非常有效。這些人口變化正在增加對 SGLT2 抑制劑等有效治療藥物的需求。 SGLT2 抑制劑可有效降低心血管和腎臟風險，尤其是老年人。這項優點使這些藥物成為老年患者的首選。據世界衛生組織 (WHO) 稱，到 2022 年，大約有 14 億人年齡在 60 歲或以上，而 2020 年這一數字為 10 億。此外，世界衛生組織預測老年人口將達21億。因此，老年人口的增加預計將增加全球對 SGLT2 抑制劑的需求並推動市場成長。

患者和醫療保健專業人員對糖尿病的認知不斷提高，以及 SGLT2 抑制劑在治療中的重要性，有助於提高處方率。例如，2021年，世衛組織啟動了全球糖尿病契約舉措，以提高意識並改善患者獲得糖尿病藥物的機會，包括 SGLT2 抑制劑和胰島素。預計此類舉措將推動 SGLT2 抑制劑的採用，並在預測期內為市場帶來新的機會。

SGLT2 抑制劑市場報告亮點

  • Jardiance（Empagliflozin）細分市場預計將在 2023 年佔據市場主導地位，並在預測期內顯著成長。這種成長是由於糖尿病、慢性腎臟病和心血管疾病的盛行率不斷上升以及治療藥物的高需求。
  • 2023年，第2型糖尿病細分市場佔據主導地位。這一優勢是由於糖尿病盛行率不斷上升、老年人口不斷增加以及藥物處方率不斷增加。
  • 2023 年，醫院藥局領域將主導市場。這一優勢是由於糖尿病、慢性腎臟病和心臟衰竭患者的診斷和治療住院人數的增加。
  • 由於先進的醫療基礎設施、目標疾病盛行率上升以及有利的法規環境等因素，北美在市場上佔據主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 SGLT2 抑制劑市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • SGLT2抑制劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析
    • 目標人口分析

第4章 SGLT2抑制劑市場：依藥物估算與趨勢分析

  • 全球 SGLT2 抑制劑市場：按藥物分類的儀表板
  • 全球SGLT2抑制劑市場：依藥物波動分析
  • 全球 SGLT2 抑制劑市場：按藥物分類的收益
  • Jardiance（Empagliflozin）
  • Farxiga（Dapagliflozin）
  • Invokana（Canagliflozin）
  • Impefa（索格列淨）
  • Qtern（Dapagliflozin/沙格列汀）
  • 其他 SGLT2 抑制劑

第5章 SGLT2抑制劑市場：按適應症估算與趨勢分析

  • 全球 SGLT2 抑制劑市場：按適應症分類的儀表板
  • 全球SGLT2抑制劑市場：按適應症的波動分析
  • 全球 SGLT2 抑制劑市場：按適應症分類的收益
  • 2型糖尿病
  • 心血管
  • 慢性腎臟病（CKD）
  • 其他

第6章 SGLT2抑制劑市場：依通路估算與趨勢分析

  • 全球 SGLT2 抑制劑市場：按分銷管道分類的儀表板
  • 全球SGLT2抑制劑市場：依通路波動分析
  • 全球 SGLT2 抑制劑市場：按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 SGLT2抑制劑市場：按藥物、適應症和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Boehringer Ingelheim International GmbH.
    • AstraZeneca
    • Merck &Co., Inc.
    • Johnson &Johnson Services, Inc.（Janssen Pharmaceuticals, Inc.）
    • TheracosBio, LLC
    • Lexicon Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Glenmark Pharmaceuticals Ltd
Product Code: GVR-4-68040-322-4

SGLT2 Inhibitors Market Growth & Trends:

The global SGLT2 inhibitors market size is anticipated to reach USD 29.43 billion by 2030 and is expected to expand at a CAGR of 7.71% during the forecast period, according to a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update to their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).

In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression to kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available to patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected to boost demand for drugs during the forecast period.

The elder adults are more prone to type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According to the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected to reach 2.1 billion. Thus, rising geriatric population is expected to boost demand for SGLT2 inhibitors worldwide and drive market growth.

Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute to higher prescription rates. For instance, in 2021, the WHO launched initiative "Global Diabetes Compact" to raise awareness and improve patient access to diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected to boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.

SGLT2 Inhibitors Market Report Highlights:

  • Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated to grow significantly over the forecast period. This growth is attributed due to increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment
  • Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due to rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug
  • Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due to increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug and Indication outlook
    • 2.2.2. Distribution Channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target disease
      • 3.2.1.2. Technological advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of drug development
      • 3.2.2.2. Stringent regulatory policies for drug approval
  • 3.3. SGLT2 Inhibitors Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

  • 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
  • 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
  • 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
  • 4.4. Jardiance (empagliflozin)
    • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Farxiga (dapagliflozin)
    • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Invokana (canagliflozin)
    • 4.6.1. Invokana (canagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Inpefa (sotagliflozin)
    • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Qtern (dapagliflozin/saxagliptin)
    • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Other SGLT2 Inhibitors
    • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

  • 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
  • 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
  • 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
  • 5.4. Type 2 Diabetes
    • 5.4.1. Type 2 diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiovascular
    • 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Chronic Kidney Disease (CKD)
    • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
  • 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
  • 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Boehringer Ingelheim International GmbH.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AstraZeneca
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. TheracosBio, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lexicon Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Eli Lilly and Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bristol-Myers Squibb Company
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Glenmark Pharmaceuticals Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 4 North America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 7 U.S. SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 10 Canada SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 13 Mexico SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Europe SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 20 Germany SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 23 UK SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 26 France SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 27 France SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 29 Italy SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 32 Spain SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 35 Denmark SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 38 Sweden SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 41 Norway SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 48 China SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 49 China SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 51 Japan SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 54 India SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 55 India SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 57 South Korea SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 60 Australia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 63 Thailand SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 67 Latin America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 70 Brazil SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 73 Argentina SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 77 MEA SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 80 South Africa SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 86 UAE SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
  • Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
  • Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 SGLT2 Inhibitors market: market outlook
  • Fig. 14 SGLT2 Inhibitors competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 SGLT2 Inhibitors market driver impact
  • Fig. 18 SGLT2 Inhibitors market restraint impact
  • Fig. 19 SGLT2 Inhibitors market: Drug movement analysis
  • Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways
  • Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Invokana (canagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 SGLT2 Inhibitors market: Indication movement analysis
  • Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways
  • Fig. 30 Type 2 diabetes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis
  • Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis
  • Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways
  • Fig. 41 Global SGLT2 Inhibitors market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players - SGLT2 Inhibitors market